Page 213 - 2019_12-Haematologica-web

Th17/Th1 inflammation in lupus atherosclerosis
Pathogenesis of antiphospholipid syn- drome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-339.
33. Laczik R, Szodoray P, Veres K, et al. Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome. Autoimmunity. 2010;43(4):334-339.
34. Matsuura E, Lopez LR, Shoenfeld Y, et al. β2-glycoprotein I and oxidative inflamma- tion in early atherogenesis: a progression from innate to adaptive immunity? Autoimmun Rev. 2012;12(2):241-249.
35. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res. 2003;59(1):234-240.
36. Lee TS, Yen HC, Pan CC, et al. The role of interleukin 12 in the development of ather- osclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19(3):734-742.
37. Whitman SC, Ravisankar P, Daugherty A. IFN-g deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res. 2002;22(6):661–670.
38. Park H, Li Z, Yang XO, et al. A distinct lin- eage of CD4 T cells regulates tissue inflam- mation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-1141.
39. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell popu-
lation that induces autoimmune inflamma-
tion. J Exp Med. 2005;201(2):233-240.
40. Korn T, Oukka M, Kuchroo V, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature.
2007;448(7152):484-487.
41. Zhu J, Yamane H, Paul WE. Differentiation
of effector CD4 T cell populations. Annu
Rev Immunol. 2010;28:445-489.
42. Eid RE, Rao DA, Zhou J, et al. Interleukin- 17 and interferon-gamma are produced concomitantly by human coronary artery- infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation.
2009;119(10):1424-1432.
43. Toschi V, Gallo R, Lettino M, et al. Tissue
factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95(3):594-599.
Basic Res Cardiol 2011;106(1):125-134.
47. Zhu M, Mo H, Li D, et al. Th17/Treg imbal- ance induced by increased incidence of ath- erosclerosis in patients with systemic lupus erythematosus (SLE). Clin Rheumatol.
2013;32(7):1045-1052.
48. Zhang L, Wang T, Wang XQ, et al. Elevated
frequencies of circulating Th22 cell in addi- tion to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome. PLoS One. 2013;8(12): e71466.
49. Zhao Z, Wu Y, Cheng M, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis. 2011;217(2):518-524.
50. Peck A, Mellins ED. Plasticity of T-cell phe- notype and function: the T helper type 17 example. Immunology. 2010;129(2):147-
44. Chen S, Shimada K, Zhang W, et al. IL-17A 153.
is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection- accelerated atherosclerosis in mice. J Immunol. 2010;185(9):5619-5627.
45. Wang T, Cunningham A, Houston K, et al. Endothelial interleukin-21 receptor up-reg- ulation in peripheral artery disease. Vasc Med. 2016;21(2):99-104.
46. Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atheroscle- rotic lesions is associated with increased inflammation and plaque vulnerability.
51. Rauch J, Salem D, Subang R, et al. β2- Glycoprotein I-Reactive T Cells in Autoimmune Disease. Front Immunol. 2018;10:2836.
52. Savino MT, Ulivieri C, Emmi G, et al. The Shc family protein adaptor, Rai, acts as a negative regulator of Th17 and Th1 cell development. J Leukoc Biol. 2013;93(4):549-559.
53. Ketelhuth DF, Hansson GK. Adaptive response of T and B cells in atherosclerosis. Circ Res. 2016;118(4):668-678.
haematologica | 2019; 104(12)
2527